Share-based Payment Arrangement, Expense of LISATA THERAPEUTICS, INC. from 31 Dec 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
LISATA THERAPEUTICS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 30 Sep 2025.
  • LISATA THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $232,000, a 29% decline year-over-year.
  • LISATA THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $1,636,000, a 9.7% increase year-over-year.
  • LISATA THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $1,653,000, a 19% decline from 2023.
  • LISATA THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $2,038,000, a 23% decline from 2022.
  • LISATA THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $2,636,000, a 31% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

LISATA THERAPEUTICS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,636,000 $232,000 -$95,000 -29% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $1,731,000 $239,000 +$2,000 +0.84% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $1,729,000 $530,000 +$76,000 +17% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $1,653,000 $635,000 +$162,000 +34% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $1,491,000 $327,000 +$21,000 +6.9% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $1,470,000 $237,000 -$347,000 -59% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $1,817,000 $454,000 -$221,000 -33% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $2,038,000 $473,000 +$4,000 +0.85% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $2,034,000 $306,000 -$734,000 -71% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $2,768,000 $584,000 +$217,000 +59% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $2,551,000 $675,000 -$85,000 -11% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $2,636,000 $469,000 +$104,000 +28% 01 Oct 2022 31 Dec 2022 10-K 29 Feb 2024 2023 FY
Q3 2022 $2,532,000 $1,040,000 +$267,000 +35% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $2,265,000 $367,000 +$97,000 +36% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $2,168,000 $760,000 +$163,000 +27% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $2,005,000 $365,000 +$191,000 +110% 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $1,814,000 $773,000 +$544,000 +238% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $1,270,000 $270,000 -$25,000 -8.5% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $1,295,000 $597,000 +$30,000 +5.3% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $1,265,000 $174,000 -$75,000 -30% 01 Oct 2020 31 Dec 2020 10-K 22 Mar 2022 2021 FY
Q3 2020 $1,340,000 $229,000 -$25,000 -9.8% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $1,365,000 $295,000 +$50,000 +20% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $1,315,000 $567,000 +$20,000 +3.7% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $1,295,000 $249,000 +$78,000 +46% 01 Oct 2019 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q3 2019 $1,217,000 $254,000 +$87,000 +52% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $1,130,000 $245,000 -$1,723,000 -88% 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020 2020 Q2
Q1 2019 $2,853,000 $547,000 +$400,000 +272% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $2,453,000 $171,000 +$89,000 +109% 01 Oct 2018 31 Dec 2018 10-K 05 Mar 2020 2019 FY
Q3 2018 $2,364,000 $167,000 +$105,000 +169% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $2,259,000 $1,968,000 -$207,000 -9.5% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $2,466,000 $147,000 -$386,000 -72% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $2,852,000 $82,000 -$295,000 -78% 01 Oct 2017 31 Dec 2017 10-K 14 Mar 2019 2018 FY
Q3 2017 $3,147,000 $62,000 -$978,600 -94% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $4,125,600 $2,175,000 +$1,839,500 +548% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $2,286,100 $533,000 -$318,200 -37% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 $2,604,300 $377,000 -$104,000 -22% 01 Oct 2016 31 Dec 2016 10-K 22 Mar 2018 2017 FY
Q3 2016 $2,708,300 $1,040,600 +$604,100 +138% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $2,104,200 $335,500 -$4,080,800 -92% 01 Apr 2016 30 Jun 2016 10-Q 10 Aug 2017 2017 Q2
Q1 2016 $6,185,000 $851,200 -$3,565,100 -81% 01 Jan 2016 31 Mar 2016 10-Q 15 May 2017 2017 Q1
Q4 2015 $9,750,100 $481,000 -$1,787,300 -79% 01 Oct 2015 31 Dec 2015 10-K 17 Mar 2017 2016 FY
Q3 2015 $11,537,400 $436,500 -$2,851,400 -87% 01 Jul 2015 30 Sep 2015 10-Q 07 Nov 2016 2016 Q3
Q2 2015 $14,388,800 $4,416,300 +$2,656,600 +151% 01 Apr 2015 30 Jun 2015 10-Q 06 Aug 2015 2015 Q2
Q1 2015 $11,732,200 $4,416,300 +$522,700 +13% 01 Jan 2015 31 Mar 2015 10-Q 09 Aug 2016 2016 Q2
Q4 2014 $11,209,500 $2,268,300 +$871,400 +62% 01 Oct 2014 31 Dec 2014 10-K 15 Mar 2016 2015 FY
Q3 2014 $10,338,100 $3,287,900 +$1,160,300 +55% 01 Jul 2014 30 Sep 2014 10-Q 05 Nov 2015 2015 Q3
Q2 2014 $9,177,800 $1,759,700 +$664,000 +61% 01 Apr 2014 30 Jun 2014 10-Q 06 Aug 2015 2015 Q2
Q1 2014 $8,513,800 $3,893,600 +$1,675,100 +76% 01 Jan 2014 31 Mar 2014 10-Q 06 May 2015 2015 Q1
Q4 2013 $6,838,700 $1,396,900 +$163,700 +13% 01 Oct 2013 31 Dec 2013 10-K 15 Mar 2016 2015 FY
Q3 2013 $6,675,000 $2,127,600 +$211,400 +11% 01 Jul 2013 30 Sep 2013 10-Q 30 Oct 2014 2014 Q3
Q2 2013 $6,463,600 $1,095,700 +$9,300 +0.86% 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014 2014 Q2
Q1 2013 $6,454,300 $2,218,500 -$258,200 -10% 01 Jan 2013 31 Mar 2013 10-Q 08 May 2014 2014 Q1
Q4 2012 $6,712,500 $1,233,200 01 Oct 2012 31 Dec 2012 10-K 02 Mar 2015 2014 FY
Q3 2012 $1,916,200 +$408,400 +27% 01 Jul 2012 30 Sep 2012 10-Q 07 Nov 2013 2013 Q3
Q2 2012 $1,086,400 -$3,659,200 -77% 01 Apr 2012 30 Jun 2012 10-Q 08 Aug 2013 2013 Q2
Q1 2012 $2,476,700 01 Jan 2012 31 Mar 2012 10-Q 09 May 2013 2013 Q1
Q3 2011 $1,507,800 01 Jul 2011 30 Sep 2011 10-Q 13 Nov 2012 2012 Q3
Q2 2011 $4,745,600 01 Apr 2011 30 Jun 2011 10-Q 14 Aug 2012 2012 Q2

LISATA THERAPEUTICS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,653,000 -$385,000 -19% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $2,038,000 -$598,000 -23% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $2,636,000 +$631,000 +31% 01 Jan 2022 31 Dec 2022 10-K 29 Feb 2024 2023 FY
2021 $2,005,000 +$740,000 +58% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $1,265,000 -$30,000 -2.3% 01 Jan 2020 31 Dec 2020 10-K 22 Mar 2022 2021 FY
2019 $1,295,000 -$1,158,000 -47% 01 Jan 2019 31 Dec 2019 10-K 25 Feb 2021 2020 FY
2018 $2,453,000 -$399,000 -14% 01 Jan 2018 31 Dec 2018 10-K 05 Mar 2020 2019 FY
2017 $2,852,000 +$247,700 +9.5% 01 Jan 2017 31 Dec 2017 10-K 14 Mar 2019 2018 FY
2016 $2,604,300 -$7,145,800 -73% 01 Jan 2016 31 Dec 2016 10-K 22 Mar 2018 2017 FY
2015 $9,750,100 -$1,459,400 -13% 01 Jan 2015 31 Dec 2015 10-K 17 Mar 2017 2016 FY
2014 $11,209,500 +$4,370,800 +64% 01 Jan 2014 31 Dec 2014 10-K 15 Mar 2016 2015 FY
2013 $6,838,700 +$126,200 +1.9% 01 Jan 2013 31 Dec 2013 10-K 15 Mar 2016 2015 FY
2012 $6,712,500 -$3,553,500 -35% 01 Jan 2012 31 Dec 2012 10-K 02 Mar 2015 2014 FY
2011 $10,266,000 +$9,698,300 +1708% 01 Jan 2011 31 Dec 2011 10-K 11 Mar 2013 2012 FY
2010 $567,700 01 Jan 2010 31 Dec 2010 8-K 15 Aug 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.